ArticleNature communications2024
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse.Nature medicine · 2026Article
- Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation.Diagnostics (Basel, Switzerland) · 2026Article
- [XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)].Revista de neurologia · 2026Article
- Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.Journal of neuroinflammation · 2026Article
- Secondary demyelination after stroke: Glial cell crosstalk.IBRO neuroscience reports · 2026Review
- A framework for blood biomarker discovery in MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Review
- Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- A Sensitive Multichannel Fluorescent Polymer Sensor Array for the Detection of Protein Fluctuations in Serum.Sensors (Basel, Switzerland) · 2026Article
- A Long-Term Prospective Evaluation of the Predictive Value of Molecular Markers in Serum and Cerebrospinal Fluid in Patients in the Early Stage of Multiple Sclerosis.International journal of molecular sciences · 2026Article
- Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types.Brain : a journal of neurology · 2025Article
- Exploring the Prognostic Role of Neurofilaments and SEMA3A in Multiple Sclerosis Progression.International journal of molecular sciences · 2025Observational
- Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Neurodegenerative Biomarkers in Multiple Sclerosis: At the Interface Between Research and Clinical Practice.Diagnostics (Basel, Switzerland) · 2025Review
- Independent and combined adverse effects of neurocognitive impairment and depression on everyday functioning and quality of life in people with HIV.Journal of the International Neuropsychological Society : JINS · 2025Article
- Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.Journal of neurology · 2025Article
- Functional and Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: Cognitive Tests and Plasma Neurofilament Light Chain Levels.Medicina (Kaunas, Lithuania) · 2025Article
- T-cell repertoire correlates with cytokine imbalance in multiple sclerosis patients.Frontiers in immunology · 2025Article
- Multi-omics-driven biomarker discovery in autoimmune diseases: a comprehensive review.Frontiers in immunology · 2025Review
- CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Emerging MRI and biofluid biomarkers in the diagnosis and prognosis of multiple sclerosis.The Lancet regional health. Europe · 2024Article
Corrections and comments
- Update of
Authors and funding
19 authors.
Funding
Abstract
The multifaceted nature of multiple sclerosis requires quantitative biomarkers that can provide insights related to diverse physiological pathways. To this end, proteomic analysis of deeply-phenotyped serum samples, biological pathway modeling, and network analysis were performed to elucidate inflammatory and neurodegenerative processes, identifying sensitive biomarkers of multiple sclerosis disease activity. Here, we evaluated the concentrations of > 1400 serum proteins in 630 samples from three multiple sclerosis cohorts for association with clinical and radiographic new disease activity. Twenty proteins were associated with increased clinical and radiographic multiple sclerosis disease activity for inclusion in a custom assay panel. Serum neurofilament light chain showed the strongest univariate correlation with gadolinium lesion activity, clinical relapse status, and annualized relapse rate. Multivariate modeling outperformed univariate for all endpoints. A comprehensive biomarker panel including the twenty proteins identified in this study could serve to characterize disease activity for a patient with multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.